Recombinant human growth hormone has been used in clinical practice for 30 years, but it needs to be injected daily. 2014 saw the launch of the world’s first PEGylated long-acting growth hormone, polyethylene glycol recombinant human growth hormone (PEG-rhGH), in China, which only needs to be injected once a week. The Department of Pediatric Endocrinology of Wuhu First People’s Hospital is honored to be selected as one of the national research centers for the “Phase IV clinical trial (multi-center, randomized, parallel, dose-control clinical study) of polyethylene glycol recombinant human growth hormone injection for the treatment of growth hormone deficiency in children”. The Phase IV clinical trial is for pharmaceuticals that have been officially approved for marketing, and continues to conduct large sample size clinical observations to further understand the safety and efficacy of Phase IV use in humans. The trial is organized and implemented by Changchun Kinsai Pharmaceuticals, with complete approval documents related to drug manufacturing, marketing and clinical trials, and a complete clinical trial protocol, patient informed consent form and research medical records and medical record report forms, and clinical study logs. The phase IV clinical trial medical ethics approval of the drug has been passed. As the only research center unit authorized to participate in this study in South Anhui, the leadership and relevant departments of Wuhu First People’s Hospital attached great importance to it and quickly completed the in-hospital review and ethical approval, and the first national “Phase IV clinical trial of polyethylene glycol recombinant human growth hormone injection for the treatment of childhood growth hormone deficiency” hospital kick-off meeting was held on On November 6, 2014, the kick-off meeting was held in the Department of Pediatric Endocrinology of the First People’s Hospital of Wuhu City. Chen Jing from the Institute of Medical Research and Strategic Planning of Kinsey Pharmaceuticals, as the supervisor of the drug clinical trial of the Center, gave a detailed explanation on the precautions related to the clinical trial process at the meeting. The principal investigator, investigator, drug administrator and serum administrator of the project in this center were also identified at the meeting. Polyethylene glycol recombinant human growth hormone injection for the treatment of childhood growth hormone deficiency phase IV clinical trial enrollment conditions: ① the height of the child is lower than the diagnostic criteria for dwarfism at the appropriate age; ② the growth hormone (GH) excitation test conducted separately for the two drugs, GH peak less than 10ng/ml, suggesting growth hormone deficiency; ③ boys with bone age less than 10 years old, girls with bone age less than 9 years old, no signs of pubertal development (ii) the age was greater than 3 years, and gender was not limited; (iii) no growth hormone treatment had been used within the last 6 months; (iv) the relevant examination excluded special diseases; (v) the subjects were willing and able to cooperate with the completion of the scheduled visit, treatment plan and laboratory tests and other test procedures, and signed the written informed consent. The enrollment observation period was 6 months, during which the initial examination, 1 month of treatment, 3 months of re-examination, and 6 months of exit examination were included. All relevant examinations, according to the clinical trial protocol, need to be performed at our center. The enrollment-related incentives: for patients who successfully enroll and complete the above-mentioned 6-month visit, all medications will be provided free of charge during the enrollment period, and examination costs will be paid for. For those who continue the medication after the end of the 6-month enrollment treatment, the medication will be provided at a buy-one-get-one-free price (slightly higher than the price of water) for the first year of continued treatment (7-18 months), the second year of continued treatment (19-30 months), the medication will be provided at a buy-one-get-one-free price (slightly higher than the price of powder), and for those who continue the treatment after that, the medication will be provided at a buy-one-get-one-free price, directly after the end of all treatment, which is equivalent to the price of short-acting powder. What you get is the convenience of long-acting growth stimulation. Patients who are enrolled in the group can register at any time for consultation at our center, regardless of the number of appointments, but it is still necessary to inform them first when they visit after enrollment, so that they can prepare case information. Polyethylene glycol recombinant human growth hormone injectable liquid (PEG-rhGH), by coupling an inert, highly hydrophilic polyethylene glycol (PEG) molecule to recombinant human growth hormone (rhGH, short-acting), increases the molecular weight and significantly prolongs the clearance process of growth hormone in the body, requiring only weekly injections. Protein drugs modified by PEG can improve the water solubility, increase biocompatibility, improve tissue distribution, reduce toxic effects, prolong circulating half-life and enhance efficacy of the modified drugs, etc. After multiple animal and clinical trials, it has been proven to be effective without increasing side effects.